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1. Introduction
Currently coronary artery bypass grafting (CABG) is the most commonly used procedure for
revascularization of coronary heart disease. However it may not be suitable for the patients with
diffuse coronary artery lesions, for which endarterectomy is a way but it’s not feasible to thin
coronary artery without inner lumen or to the immature plaque. In this case, it may be a proper
therapeutic option to achieve coronary revascularization by retrograde perfusion via cardiac
venous system, namely retrograde coronary venous bypass grafting (CVBG). [1] Saphenous
veins could be used to realize arterialization for great or middle cardiac vein by separate or
sequential bypass grafting. But it would cause myocardial hemorrhage, edema and even heart
failure due to excessive perfusion by high pressure [2]. However, internal mammary artery
(IMA), as one kind of muscular artery materials, can enlarge or contract its lumen to adjust the
blood flow with strong adaptability [3]. Off-pump coronary artery bypass surgery (OPCAB)
has been widely applied as a less invasive method of myocardial revascularization in recent
years. It could avoid the systemic inflammatory effects caused by cardiopulmonary bypass
(CPB). OPCAB has more merits such as low mortality, low morbidity, and reduced costs,
especially in high risk patients [4]. Therefore, sequential bypass of bilateral IMA combined with
arterialization for middle cardiac vein were carried out during OPCAB for patients with diffuse
lesions existing in right coronary artery.
2. Definition & anatomy
Diffuse CAD was defined as: length of significant stenoses ≥20 mm; multiple significant
stenoses (≥70% narrowing) in the same artery separated by segments of apparently normal
(but probably diseased) vessel; and significant narrowing involving the whole length of the
coronary artery [5] (Figure 1). Provided a mature plaque is successfully endarterected through
© 2013 Gu et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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the true arterial lumen (Figure 2)., patients with a long diffuse lesion can be treated very
efficiently. But sometimes long, severe diffuse coronary artery stenosis isn’t recommended for
surgical treatment because of its low patency and more postoperative complications [6].
(Figure 3)
Figure 1. Diffuse CAD of the right coronary artery
3. History
The idea that the mammalian myocardium could be nourished by means of a flow of blood
from the coronary venous system, acting as an alternative myocardial perfusion way because
it would not be affected by atherosclerosis, was proposed by Pratt in 1898 [7]. However, few
clinical trials and long-term outcome data have been presented and clinical use of venous
arterialization has rarely been reported. Further experiments were made in 1943, in which the
coronary sinus in a canine model was arterialized by using an autologous carotid artery as a
conduit between the dogs descending aorta and the coronary sinus. In 1948, Beck and
colleagues first carried out blobally retroperfusion by CVBG through coronary sinus[8]. These
Artery Bypass278
Figure 2. Mature plaque in the blocked coronary artery
Figure 3. Diffuse coronary artery with immature plaque
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 l ue in the blocked coronary artery  
(Notice: the figure is removed at the request of the copyright holder [2016-06-21])
findings led them to state that there are communications between the venous and arterial sides
of the circulation which, in the dead specimen, allowed blood flow in a retrograde direction.
The Beck II procedure afterwards consisted of a free vein graft from the aorta to the coronary
sinus, with a second operation 2 to 3 weeks later to ligate the coronary sinus, which reported
remarkable success in attempts to revascularize the heart. The effectiveness of reversing flow
in the coronary venous system had been debated and this operation was gradually abandoned
because of related mortality of 26.1% and development of CABG. However, CABG was soon
discovered to have its own limitations, particularly in patients with diffuse atherosclerotic
lesion and tiny coronary arteries. Arterialization of coronary veins therefore regained its
appeal. Arealis and colleagues brought forth selective CVBG in 1973 which was made only for
part of ischemic myocardium, while normal reflux was kept for the rest myocardial veins.
Great cardiac vein parallel to LAD and middle cardiac vein parallel to PDA were selected as
goal vessels. Eventually an ample report of CVBG animal trial was published by Dr. Hochberg
in 1979which indicated CVBG’s advantages, such as perfusion all layers of the myocardium,
especially the subendocardium – the crucial layer of myocardial muscle[2]. However, this
mechanism had been studied at the experimental level because its relatively high clinical
mortality and was only theoretic until CVBG technique developed in the recent years.
4. Preclinical study and animal trials
Historically, most studies of revascularization have been based on and reported according to
angiographic  criteria.  Some patients  with significant  arteriosclerosis  of  the heart  are  not
amenable  to  revascularization of  a  coronary artery  because  they have a  combination of
microangiopathy and significant macroangiopathy. Therefore cardiac surgeons developed the
technical approach of venous revascularization. Several systematic reviews have been conduct‐
ed in an attempt to define the exact role of animal models as platforms for future human therapy
[9-12].We investigated the benefit of arterialization of a cardiac vein under these circumstan‐
ces in some animal models [13] which indicate retrograde venous revascularization is possi‐
ble and improves cardiac function in a state of acute ischemia so we could find its way into
practical use in coronary heart surgery. In experimental studies in a variety of animals and in
human clinical studies, retroperfusion of the coronary sinus has been used to improve myocar‐
dial perfusion and postischemic systolic and diastolic function in many surgical procedures. In
addition, animal trials, mostly involving sheep, dogs and pigs showed that arterialization of
cardiac veins decreases infarct size as well[11,14]. These animal models are likely to be useful
for pre-clinical evaluation of the functional effects of surgical therapy.
5. Surgical option – CVBG versus traditional CABG
There is no doubt that for patients with surgical triple-vessel coronary disease and a severely
diseased left main artery, CABG appears to be preferable [15]. Despite constant advances in
surgical and interventional therapy of coronary artery disease, there remains a group of
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patients who are not amenable to these traditional treatment strategies. Many patients being
referred for CABG nowadays have far advanced CAD, which is often diffuse and exhibits poor
vessel runoff. The idea of myocardial revascularization by means of grafting the coronary
venous system is more than a century old; in cases of diffuse coronary artery disease, this may
represent a valid therapeutic option [16].
The lack of suitable targets vessels remains a challenge for aortocoronary bypass grafting in
diffuse coronary heart disease. Although this figure approximates 20% to 50% frequency
reported in many series [17], our study represents a highly selective group with diffuse
coronary disease in which CABG was not feasible with or without an endarterectomy.
5.1. Data analysis
From March 2004 to August 2010, patients with diffuse right coronary lesions were studied
retrospectively and divided into two groups (Table1). Informed consent and ethical review
committee approval were obtained. Group 1 included seventeen patients who underwent
selective CVBG during OPCAB while group 2 included twenty-one patients without right
coronary artery surgical therapy. Group 1 included eleven male cases (64.7%), the mean age
was (46.1±6.2) years, seven hypertension cases (41.2%) and ten diabetes mellitus (58.8%) cases
were involved. The case number of cardiac function from II–IV grade was eight, eight, and one
respectively. Left ventricular ejection fraction (LVEF) was 0.52±0.09 and left ventricular end
diastolic diameter (LVEDD) was (52.7±5.1) mm. Group 2 included fourteen male cases (66.7%),
the mean age was (45.9±5.7) years, nine hypertension cases (42.9%) and eleven diabetes
mellitus (52.4%) cases were involved. The case number of cardiac function from II–IV level
was twelve, seven, two respectively. LVEF was 0.52±0.11 and LVEDD was (51.9±5.2) mm. There
was no significant difference between the two groups (P >0.05). All the patients had angina
pectoris symptom before operation. It was indicated by electrocardiogram that all the cases
with old myocardial infarction had obvious ST-T changes. Coronary angiography showed that
seven cases had double-vessel lesions and ten cases had triple-vessel lesions in group 1; nine
cases had double-vessel lesions and twelve cases had triple-vessel lesions in group 2. Right
coronary artery of all the patients took on diffuse lesions with vascular diameter <1 mm and
length >20 mm. It was shown by vascular ultrasound examination that blood flow in bilateral
mammary artery was smooth and vascular diameter >2 mm; and left subclavian artery was
not narrow.
OPCAB was performed with an average of 3.6 grafts per patient, group 1 being (3.3±1.1) grafts
and group 2 being (2.2±1.6) grafts respectively. These patients discharged eight to fourteen
days after the operation. Determination of blood flow was made for eleven cases in group 1
and thirteen cases in group 2 which were (81.47±32.65) ml/min and (76.82±28.36) ml/min in
trunk of IMA, (32.52±18.82) ml/min and (28.12±16.71) ml/min in trunk of left IMA, (39.63 ±19.02)
ml/min and (35.92±18.34) ml/min in trunk of right IMA. The both groups had no death.
Tracheal cannula was pulled out on the date of operation or one day after operation. Low-dose
positive inotropic drugs were used as assistance for four cases postoperatively. All the patients
had no brain complication and no infection of sternum and mediastinum.
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5.2. Surgical procedure
5.2.1. General surgical procedure
In group 1, standard median sternotomy incision was applied for the exposure of the heart
under general anesthesia. Bilateral IMAs were harvested as longer as possible and usually cut
proximally at the starting position from subclavian artery and distally on the level of Xiphoid.
Surrounding tissues of IMA were desected and removed so as to ensure enough length of IMA
(generally 18–25 cm). The free right IMA was anastomosed with left IMA to form a bifurcation
as “Y” type. The anastomotic position on the LIMA should be determined according to its
length and the distance from the bypass grafting anastomosis between LIMA and LAD or
diagonal. The position was usually selected at the location of 3–4 cm proximal to the first
anastomotic site of left IMA, and 8-0 prolene suture was utilized in end-to-side anastomosis
between two mammary arteries. Subsequently, CABG was carried out on beating heart. Left
IMA was anastomosed to left anterior descending artery (LAD) and then right IMA was
sequentially anastomosed with diagonal branch and circumflex artery (obtuse marginal and
posterior branch of the left ventricle). Then the end of middle cardiac vein proximal to heart
was blocked with 6-0 prolene suture so that blood can not reflow to coronary sinus in normal
way. Finally, end-to-side anastomosis between middle cardiac vein parallel to right coronary
post descending artery (PDA) and right IMA was performed with 8-0 prolene suture. When
all the vessels were anastomosed and blood circulation was stable, blood flow of grafting
vessels was determined by Transonic H1311 flowmeter (Transonic Systems, Inc., Ithaca, NY,
USA). Incision was carefully washed before closing chest. In group 2, no branch of the right
coronary artery was bypass grafted.
Group 1
N=17
Group 2
N=21
Gender (M/F) 11/6 14/7
Age (years) 46.1±6.2 45.9±5.7
Hypertension (yes/no) 7/10 9/12
Diabetes mellitus (yes/no) 10/7 11/10
LVEF 0.52±0.09 0.52±0.11
LVEDD (mm) 52.7±5.1 51.9±5.2
Coronary angiography
Double-vessel lesions 7 9
Triple-vessel lesions 10 12
LVEF: Left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter.
Table 1. Characteristics of patients
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5.2.2. Unique surgical procedure – Blood flow limitation
Venous arterialization occurs when a vein segment is transposed as a bypass graft into the
arterial circulation, and atherosclerosis is a common feature of autogenous vein bypass grafts
resulting in their long-term failure [18-20]. Arterial pressure-induced distension is thought to
play a major role in the wall thickening of vein grafts, which may in turn favor atherosclerotic
complications [21,22]. Reduction of the wall distension by perfusion pressure reduction using
blood flow limitation protected the vein grafts from atherosclerosis, possibly as a result of the
decrease in wall thickening that occurred in response to arterialization [23,24].
Saphenous vein was commonly used to complete CVBG. After harvesting, meticulous care
should be taken to avoid distention of the vein graft. An infusion pressure of no more than 100
mmHg is recommended for minimal endothelial damage [25]. In our previous study and
emerged that ischemia and infarction of myocardium would happen if the blood flow in
grafting vessel was less than 50 ml/min. The blood was delivered into the cardiac veins by the
native arterial pressure, However when intravascular pressure reached 60 mm Hg (1 mmHg
= 0.133 kPa) or higher, the risk of complications would increase such as myocardial edema and
even intramural hemorrhage and so on [26]. In this case, we used to ligate the vein graft to 1.5
to 2 mm in diameter with two interrupted silk lines to control blood flow (Figure 4). It has been
reported that infarct size can be reduced by which arterial blood is delivered retrogradely to
the ischemic myocardium through the cardiac veins [27].
Figure 4. Flow-limited CVBG
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5.3. Follow up
Three months after discharge, all the patients in group 1 had no preoperative symptom.
Myocardial ischemia was not found by electrocardiogram in group 1. Postoperative angina
was found in eight cases of group 2 and electrocardiogram showed inferior wall myocardial
ischemia. There was significant difference between the two groups (P <0.05). Cardiac function
was improved to class I (P <0.001), LVEF was increased to 0.60±0.08 (P <0.001) in group 1 and
0.56±0.10 (P <0.001) in group 2 which showed no preoperative differences and the postopera‐
tive LVEF of group 1 was superior to group 2 while there was no significant difference between
these two groups. LVEDD decreased to (48.1±3.4) mm (P <0.001) in group 1 and (47.2±3.5) mm
(P <0.001) in group 2. Patients underwent physical examination and echocardiography in our
outpatient clinic periodically after discharge. These data were compared with the patients’
preoperative variables. Several examination of myocardial nuclide imaging, coronary angiog‐
raphy (41 months postop.) and CT scanning (5 years postop.) were carried out (Figure 5).
Figure 5. follow-up CT scanning data of CVBG.
6. Conclusion
In the past few decades, there was an increase in the number of patients with coronary heart
disease who were not eligible for standard procedures including CABG and percutaneous
coronary angioplasty, and diffuse coronary atherosclerosis occupies 12%–30% of patients
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requiring further intervention [28]. Clinical trials investigating treatment with angiogenesis
factors and gene therapy have been initiated, and new devices for creating cardiac arteriove‐
nous fistulas percutaneously have also been introduced [29-32]. Whereas injection of growth
factors require an adequate arterial inflow, which is not often existent in the hearts of these
“no option patients”. New catheter devices to create a fistula between a coronary artery and
the accompanying vein or, as performed in animal experiments, a coronary vein and the left
ventricle, are difficult to handle, and hold all the risks of catheterization of a severely altered
vessel [33]. Before that, small numbers of reports of the clinical application had published, so
no remarkable conclusions can be yet drawn [34-37]. As the efficiency of these new methods
awaits the evaluation of long-term trials, we think that some patients might benefit from the
revival of an “old” procedure that is retrograde venous revascularization. In both short and
long-term experiments, effective selected area perfusion had been achieved.
Despite the successful and widespread application of these revascularization procedures, a
large number of patients are not good candidates for either angioplasty or surgery. These “no-
option” patients frequently have diffuse coronary disease without a discrete target for
angioplasty, stenting, or surgical bypass [33].In clinical application, we draw some experiences
as follows. Blood flow of IMA is important to ensure perfusion of myocardium after bypass
grafting which can be determined by preoperative vascular ultrasound examination and
intraoperative testing. It is also important to make sure the diameter of each anastomotic
incision 1.5 times as that of IMA in order to keep adequate blood flow. For the patients with
coronary vessel less than 1.5 mm in diameter, it is necessary to use 8-0 prolene suture in case
of anastomotic stricture. Attention should be focused on not damaging the posterior wall of
middle cardiac vein while opening it, because the vascular wall of coronary vein is obviously
thinner than that of coronary artery. The graft should be fixed to myocardium on both sides
because IMA and middle cardiac vein are prone to twist due to different thickness of vascular
wall. It is valuable to observe the difference of color on both segments of middle cardiac vein
in the ligation. If red and dark are distinctive, it is indicated the ligation is definite. Otherwise
it is possible that there is some residue blood flow [38]. It is useful to measure blood flow of
each graft with flowmeter after anastomosis in order to keep vessel grafting patent.
CVBG surgery is indicated for both the relief of symptoms and the improvement of life
expectancy in patients suffering from diffuse coronary heart disease [39-41]. We believe the
selective CVBG should be considered in cases of coronary artery disease not amenable to
traditional revascularization strategies [42-45]. Indications of selective CVBG include the
patients with tenuous right coronary artery or diffuse lesions. It is possibly fit for the patients
who need reoperation of CABG as well [46-48]. A substantial improvement in the long-term
prognosis may be expected with more precise anastomosis.
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